Quentis Therapeutics

What Quentis Therapeutics does

Quentis Therapeutics is a private, for-profit biotechnology company founded in 2016 and headquartered in New York, United States. The company develops immuno-therapeutics designed to address endoplasmic reticulum (ER) stress — a cellular dysfunction implicated in multiple disease states. By targeting this biological mechanism across indications, Quentis is structured around a platform-style therapeutic approach rather than a single-asset focus. The company operates at preclinical/early-stage scale, with 11-50 employees and no products on market.

Quentis's capital base consists of approximately $49 million raised across two 2018 financing events: a $48 million round led by Polaris Partners and Versant Ventures with participation from a syndicate of strategic pharmaceutical investors (AbbVie, Taiho Pharmaceutical) and venture investors (Alexandria Venture Investments, New York Ventures, Yonghua Capital), followed by a $1 million award from the New York City Economic Development Corporation (NYCEDC) in December 2018. The presence of major pharma strategics in the cap table provides early validation and a foundation for future partnership or licensing optionality, though no such deals are disclosed in the available data.

As a private preclinical biotech, Quentis's business model is predicated on advancing therapeutic candidates through R&D milestones with the implicit value-creation pathway being out-licensing, strategic partnership, or acquisition by larger pharmaceutical companies. The company has not disclosed any products, services, pricing, customer segments, revenue, or go-to-market motion in the input data, consistent with its pre-commercial stage of development.

Name

Quentis Therapeutics

Website

https://quentistx.com

Company type

Private

Founded year

2016

Headcount range

11–50 employees

Short description

Quentis Therapeutics is a New York-based private biotechnology company founded in 2016 that develops immuno-therapeutics targeting endoplasmic reticulum (ER) stress across multiple disease indications, operating at preclinical stage with 11-50 employees and approximately $49 million in total funding.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Immunotherapy development
• ER stress therapeutics
• Biopharmaceutical drug discovery
• Immuno-therapeutic pipeline
• Cell stress biology research

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Core offering

Quentis Therapeutics is a biopharmaceutical company developing immuno-therapeutic drug candidates that target endoplasmic reticulum (ER) stress, a cellular pathology implicated in multiple diseases. The company's pipeline is oriented toward translating ER stress biology into therapeutics applicable across several disease areas. Its funding profile, including a $48 million venture round led by Polaris Partners and Versant Ventures and a strategic investment from AbbVie, indicates a partnership-oriented development model typical of early-stage immuno-therapeutics developers.

Differentiator

Problem solved

Functional benefit

Products and services

• ER stress-targeting immuno-therapeutic pipeline A development-stage immuno-therapeutic pipeline composed of drug candidates designed to address endoplasmic reticulum (ER) stress across multiple disease areas; intended for in-licensing, co-development, or partnership with larger pharmaceutical companies.

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights3 records

Broad incumbents

• Taiho Pharmaceutical: Japanese specialty pharma with oncology and immuno-therapeutic focus and a Series A investor in Quentis; relevant incumbent and potential regional partner for Quentis's programs.
• AbbVie: Large pharma immunology leader and a strategic investor in Quentis; broadly comparable therapeutic area (immunology, immuno-oncology) and a likely acquirer or partner for Quentis programs.
• Bristol-Myers Squibb: Global immuno-oncology incumbent with broad immunology and ER-stress-adjacent pipeline; relevant incumbent for benchmarking indication strategy and partnership economics.

Direct peers

• Proteostasis Therapeutics: Was a direct peer developing therapeutics targeting the unfolded protein response / ER stress pathway for diseases including cystic fibrosis and neurodegeneration; most directly comparable mechanism to Quentis.
• Calporta Therapeutics: Preclinical biotech focused on selective modulators of the unfolded protein response for neurodegeneration and metabolic disease; same ER stress mechanism and comparable development stage, acquired by Merck in 2022.
• HiberCell: Immuno-oncology biotech focused on stress biology pathways (including ER stress and hypoxia) to develop therapeutics against cancer; comparable mechanism and stage to Quentis.

Emerging players

• Werewolf Therapeutics: Clinical-stage immuno-oncology biotech developing novel immunotherapies; comparable in therapeutic modality (immuno-therapeutics), target indications, and stage of development.
• Inhibrx: Clinical-stage biotech developing novel biologics for oncology and rare diseases; comparable in modality (biologic immuno-therapeutics) and as a lean private biotech with strategic optionality.
• Arcus Biosciences: Clinical-stage immuno-oncology biotech developing immuno-therapeutics; comparable in modality, disease focus, and as a mechanism-driven private-to-public biotech platform.

Others

• Versant Ventures: Lead Series A investor in Quentis; relevant ecosystem comparable as a creator of similar mechanism-driven biotech platforms (e.g., Inception Therapeutics, Chinook) — useful proxy for understanding Quentis's likely development path.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

• Xx.com/QuentisTx

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quentis Therapeutics